Navegando por Autor "Pos, Alexandre Mio"
Agora exibindo 1 - 1 de 1
- Resultados por Página
- Opções de Ordenação
Item Avaliação da qualidade de vida e analgesia de pacientes com tumores sólidos e em uso de opióides(Faculdade Ciências Médicas de Minas Gerais, 2019-05-17) Pos, Alexandre Mio; Wainstein, Alberto Julius Alves; Wainstein, Ana Paula Drummond LageIntroduction: Use of opioid analgesics remains being the main therapy for pain control in cancer patients. However, ample evidence persists showing that treatment is still inadequate. Data on this dilemma and its impact on patients' lives are still scarce in our population. Objective: To evaluate the impact of opioid use on analgesia and qual ity of life of patients with solid tumors. Material and Methods: This cross-sectional, analytical study was carried out between January and December 2017 in a Tertiary Referral Unit for Cancer Treatment. The pain, depression and quality of life were eval uated through validated instruments that included the Pain Management Index (PMI), European Organization for Research and Treatment of Cancer-Core 30 (EORTEC QLQ.C30), Beck Depression Inventory (BDI), Karnofsky Performance Status (KPS), Douleur Neuropathique 4 (DN4), Brief Pain Inventory-Short Form (BPI-SF). Results: 100 patients with advanced solid tumors and making use of opioids were studied. 82% of them reported daily pain being 58% with intense pain. 57% were making use of morphine with a mean dose of 49 Morphine Milligram Equivalent (MME) and PMI was negative in 34% of sample. Neuropathic pain (NP) was found in 72% and BDI was greater than 12 in 90% of patients. The pain was related to all BPI variables, mood, general activity, work and pleasure of living. Conclusion: Despite the substantial neg ative impact of pain on QOL, no international consistency was found among the clinical factors studied with QOL itself. This gap can be interpreted due to persistence of high levels of subtreatment, depression and neuropathic pain, associated with the use of low doses of opiates and adjuvant drugs in the sample